Genmab — December 2021
-
-
God morgen.
-
Denne onkolog undrer sig over hvorfor man overhovedet vil anvende CAR-T i MM, når man snart kan få Teclistamab som vil være „safer, better, easier and cheaper“ https://twitter.com/drpaulydesantis/status/1466262720127258625?s=21
-
Roche notes that POLARIX is the first positive DLBCL Phase III study in a curative setting for two decades. Furthermore, it has suggested that sales of Polivy could peak at around $2 billion if the antibody-drug conjugate (ADC) becomes established as a new standard of care in the first-line setting.
-
Taking efficacy and safety into account, results from POLARIX were described by 44% of oncologists as clinically meaningful and by a further 40% as promising, suggestive that physicians still want to see further detailed results and ideally a survival benefit (despite DLBLC being a relatively slowly progressing disease).
-
For 6 programs Zymeworks got 50 million dollars upfront and are eligible for up to $282M in development milestone payments as well as $1.12B in commercial milestones. Thats about 233 milliion dollars pr program which is bit more than Genmabs deal but also 5 years later. So kind of the same I guess.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind